Benign prostatic hyperplasia - A novel autoimmune disease with a potential therapy consequence?

Area of Science:

• Urology
• Immunology
• Pathophysiology

Background:

• Benign prostatic hyperplasia (BPH) is an age-related condition with unclear causes, though chronic inflammation is implicated.
• Autoimmune responses are increasingly recognized in prostate inflammation, with higher BPH prevalence in autoimmune disease patients.

Purpose of the Study:

• To explore the potential role of autoimmune responses in BPH pathophysiology.
• To investigate the efficacy of immunosuppression in managing BPH symptoms.
• To identify potential autoimmune markers for BPH.

Main Methods:

• Review of evidence linking autoimmune diseases and BPH.
• Analysis of the effects of TNF-alpha blockers on BPH symptoms and inflammation.
• Discussion of novel diagnostic targets like HEp-2 cells and mitochondrial DNA.

Main Results:

• Immunosuppression with TNF-alpha blockers reduced BPH symptoms and inflammation in patients with concurrent autoimmune disease.
• Elevated BPH prevalence observed in individuals with autoimmune conditions.
• Potential diagnostic biomarkers for autoimmune responses in BPH identified.

Conclusions:

• Autoimmune responses are likely involved in BPH pathogenesis.
• BPH may represent a novel autoimmune condition in males.
• Targeting autoimmune mechanisms offers a new therapeutic avenue for BPH.